سعر هالوبيريدول ريتارد 50 مجم/مل 2024

• Postmarketing reactions listed in the US label include urinary retention, priapism, gynaecomastia, laryngeal oedema, bronchospasm, laryngospasm, dyspnoea, angioedema, exfoliative dermatitis, photosensitivity, urticaria, pruritus, rash and hyperhidrosis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated in severe toxic CNS depression or comatose states from any cause, and in known hypersensitivity to haloperidol or any component (anaphylactic reactions and angioedema have been reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death; haloperidol is not approved for dementia-related psychosis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Cases of sudden death, QT prolongation and torsades de pointes have been reported in patients receiving haloperidol.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Tardive dyskinesia (potentially irreversible involuntary movements) may develop; risk is believed to increase with treatment duration and cumulative dose, and appears highest in the elderly, especially elderly women.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Neuroleptic malignant syndrome (hyperpyrexia, muscle rigidity, altered mental status, autonomic instability; may include raised CPK, rhabdomyolysis and acute renal failure) has been reported and is potentially fatal.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• QT-prolonging drugsAvoid concomitant use with other drugs known to prolong the QTc interval; if unavoidable, monitor ECG and electrolytes.DailyMed (U.S. National Library of Medicine)

• Published epidemiological data in pregnant patients exposed to haloperidol have not established a drug-associated risk of major birth defects or miscarriage; case reports of limb malformations exist but causality is not established. Neonates exposed in the third trimester are at risk of extrapyramidal and/or withdrawal symptoms.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Haloperidol is detected in human milk (relative infant dose about 2-12%); monitor breastfed infants for excessive sedation, irritability, poor feeding and extrapyramidal symptoms, and weigh breastfeeding benefits against the mother's need for treatment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Leukopenia, neutropenia and agranulocytosis have been reported with antipsychotics including haloperidol; risk factors include pre-existing low WBC and a history of drug-induced leukopenia/neutropenia. Monitor CBC in such patients and consider discontinuation if a clinically significant decline in WBC occurs without other cause.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• When concomitant QT-prolonging drugs cannot be avoided, obtain ECGs and serum electrolytes (potassium, calcium, phosphorus, magnesium) at initiation and during concomitant use as clinically indicated.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.